Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697773 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 698
- Enrollment target
NCT02697773 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 698 participants.
The verdict
NCT02697773, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 698 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study also evaluates the safety of the treatment regimens.
Interventions
- OTHER Placebo
- BIOLOGICAL Tanezumab 2.5 mg
- BIOLOGICAL Tanezumab 2.5mg/5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2016-01-21 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697773
The ClinicalTrials.gov registry entry for NCT02697773 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 698 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02697773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697773 about?
NCT02697773 is a clinical study titled "Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee". The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg) at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study also evaluates the saf...
What is the current status of trial NCT02697773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 698 participants. The study started on 2016-01-21. Estimated completion is 2018-05-14.
What interventions are being tested in trial NCT02697773?
The interventions under investigation include: Placebo (OTHER), Tanezumab 2.5 mg (BIOLOGICAL), Tanezumab 2.5mg/5mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02697773?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.